13 completed, 4 not yet recruiting, 4 recruiting, 4 terminated. 32 Phase 2, 3 Phase 1, 3 Phase 3.
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NM8074 - IgA Nephropathy | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 10 | 2028-02-01 | 2026-04-13 |
| Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy Mycophenolate Mofetil (MMF), Prednisolon - IgA Nephropathy | Phase 2 | Not yet recruiting | Shaheed Suhrawardy Medical College and Hospital | 104 | 2026-09-01 | 2026-08-25 |
| A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G ADX-097 - IgA Nephropathy, Lupus Nephritis (LN) | Phase 2 | Recruiting | Akebia Therapeutics | 30 | 2026-07-30 | 2026-10-01 |
| A Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101 - IgA Nephropathy | Phase 2 | Recruiting | Jade Biosciences, Inc. | 30 | 2026-05-19 | 2026-10-30 |
| Study of CM313 in Subject With IgA Nephropathy CM313, Placebo - IgA Nephropathy | Phase 2 | Not yet recruiting | Keymed Biosciences Co.Ltd | 106 | 2025-09-01 | 2025-09-19 |
| Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Hydroxychloroquine Oral Tablet, Placebo oral tablet - IgA Nephropathy | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 334 | 2025-06-26 | 2026-10-09 |
| A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases SCTC21C - IgA Nephropathy | Phase 1 / Phase 2 | Not yet recruiting | Sinocelltech Ltd. | 99 | 2025-01-01 | 2025-01-14 |
| A Phase IIa Study in Primary IgA Nephropathy Patients XH-S003 Capsule - IgA Nephropathy | Phase 2 | Completed | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 25 | 2024-12-31 | 2026-09-25 |
| Phase 2b Open-Label Repeat Kidney Biopsy Study Sibeprenlimab - IgA Nephropathy | Phase 2 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 56 | 2024-12-05 | 2026-10-27 |
| Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Atrasentan, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 2 | Completed | Novartis Pharmaceuticals | 54 | 2023-07-20 | 2026-07-20 |
| A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease Placebo of SC0062, SC0062 low dose, SC0062 medium dose - Diabetic Kidney Disease, IgA Nephropathy | Phase 2 | Unknown | Biocity Biopharmaceutics Co., Ltd. | 255 | 2023-05-23 | 2025-01-07 |
| Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy CM338 - IgA Nephropathy | Phase 2 | Recruiting | Keymed Biosciences Co.Ltd | 70 | 2023-05-08 | 2024-10-15 |
| Study of Telitacicept in Patients With Refractory IgA Nephropathy Telitacicept - IgA Nephropathy | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 40 | 2023-03-01 | 2023-02-24 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy | Phase 2 | Terminated | RemeGen Co., Ltd. | 15 | 2021-11-04 | 2023-12-06 |
| A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. HR19042 Capsules, Placebo - IgA Nephropathy | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 316 | 2021-09-09 | 2026-03-12 |
| Atrasentan in Patients With Proteinuric Glomerular Diseases Atrasentan - IgA Nephropathy, Focal Segmental Glomerulosclerosis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 103 | 2021-03-15 | 2026-06-01 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
Showing 20 of 32. Sign in to see all of them.
Glomerulonephritis, IGA (32) · Proteinuria (6) · Kidney Diseases (4) · Glomerulonephritis (3) · Diabetic Nephropathies (2) · Glomerulosclerosis, Focal Segmental (2) · Lupus Nephritis (2) · Renal Insufficiency, Chronic (2) · Urologic Diseases (2) · Autoimmune Diseases (1) · Complement Component 3 Deficiency, Autosomal Recessive (1) · Glomerulonephritis, Membranoproliferative (1) · Glomerulonephritis, Membranous (1) · Immune System Diseases (1) · Nephritis (1)
Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Male Urogenital Diseases (32) · Autoimmune Diseases (31) · Immune System Diseases (31) · Nephritis (31) · Urogenital Diseases (31) · Urologic Diseases (30) · Glomerulonephritis (29) · Kidney Diseases (28) · Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (6) · Urination Disorders (6) · Urological Manifestations (6) · Connective Tissue Diseases (3)
Atrasentan (2) · fostamatinib (2) · telitacicept (2) · AMG623 peptibody (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Anti-Inflammatory Agents (1) · Budesonide (1) · Fecal Microbiota Transplantation (1) · Hydroxychloroquine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Mycophenolic Acid (1) · Prednisolone (1) · Sirolimus (1) · TACI receptor-IgG Fc fragment fusion protein (1) · Tacrolimus (1)
Novartis Pharmaceuticals (4) · Keymed Biosciences Co.Ltd (2) · Rigel Pharmaceuticals (2) · Air Force Military Medical University, China (1) · Akebia Therapeutics (1) · Anthera Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Aravive, Inc. (1) · Arrowhead Pharmaceuticals (1) · Astellas Pharma Inc (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Biogen (1) · Calliditas Therapeutics AB (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · EMD Serono Research & Development Institute, Inc. (1)
United States (12) · China (10) · United Kingdom (9) · South Korea (8) · Australia (6) · Germany (4) · Malaysia (4) · Spain (4) · Taiwan (4) · Thailand (4) · Brazil (3) · Hong Kong (3) · Japan (3) · New Zealand (3) · Argentina (2)
Jicheng Lv (2) · Francoise Desir (1) · Hong Zhang (1) · Jianghua Chen, Prof (1) · Josep M Cruzado, Medical Doctor (1) · Li Li, MD (1) · Meritxell Ibernon, MD (1) · Mohammad Naheed Hasan (1) · Shiren Sun, M.D. (1)
PMID 38299639, PMID 26032537, PMID 23977072, PMID 30177021, PMID 34124781, PMID 37036696, PMID 37254256, PMID 39462310, PMID 39899371, PMID 40482854, PMID 40938675, PMID 41442197, PMID 41904616
2023 (2), 2005 (1), 2014 (1), 2016 (1), 2017 (1), 2018 (1)